The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Open accessAbstract
BACKGROUND: BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers. METHODS: We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort. A total of 122 patients with BRAF V600 mutation-positive cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab. The primary end point was the response rate; secondary end points included progression-free and overall survival. RESULTS: In the cohort with non-small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 months (95% CI, 3.5 to 10.8). In the cohort with Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 months (range, 0.6 to 18.6), and no patients had disease progression during therapy. There were anecdotal responses among patients with pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal cancer who received vemurafenib and cetuximab. Safety was similar to that in prior studies of vemurafenib for melanoma. CONCLUSIONS: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers. Preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis. The histologic context is an important determinant of response in BRAF V600-mutated cancers. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT01524978.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, in BRAFV600 colorectal cancer, targeting EGFR—the RTK thought to be the primary driver of feedback reactivation from preclinical studies—in combination with BRAF inhibition, has led to an improvement in clinical efficacy (34–39).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors have proven ineffective as single agents due to adaptive feedback re-activation of the MAPK and other signaling pathways [5–13, 38].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF inhibitor monotherapy is a promising treatment of many cancers, including melanoma and NSCLC; however, BRAF inhibitor efficacy in colorectal cancer patients with BRAF V600E mutations is limited (21).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast with other BRAFV600E tumors (i.e. melanoma), BRAFV600E-targeted therapy (like vemurafenib) has proven largely ineffective in CRC, with response rates <5% as single agents [5, 6].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
In the citing paper
“However, in another clinical study, CRC patients did not benefit from vemurafenib monotherapy and/or cetuximab [161].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [161]
In the citing paper
“However, a multicentric clinical study containing 27 CRC patients showed that vemurafenib alone or with cetuximab did not benefit CRC patients [99].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Flagged first, then by citations
Research works printed but not linked: 1
- Kimura ET, 2003, Cancer Res, 63, 1454
Cited by
Sorted by citations
Items 201–300 of 1,002
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Guo, H., Zhang, J., Qin, C., Yan, H., Liu, T., Hu, H., Tang, S., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11203200 · Cited by 123
Eckstein, O. S., Visser, J., Galindo, C. R., Allen, C. E., & the NACHO-LIBRE Study Group (2019) · Blood · doi:10.1182/blood-2018-10-878363 · Cited by 123
Master protocol trials in oncology: Review and new trial designs
Hirakawa, A., Asano, J., Sato, H., & Teramukai, S. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.009 · Cited by 120
Hayashi, H., Takiguchi, Y., Minami, H., Akiyoshi, K., Segawa, Y., Ueda, H., Iwamoto, Y., Kondoh, C. N., Matsumoto, K., Takahashi, S. I., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4643 · Cited by 117
König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 119
Boon, E., van Boxtel, W., Buter, J., de Jong, R. J. B., van Es, R. J. J., Bel, M., Fiets, E., Oosting, S. F., Slingerland, M., Hoeben, A., et al. (2017) · Head & Neck · doi:10.1002/hed.25035 · Cited by 116
Development of genome-derived tumor type prediction to inform clinical cancer care
Penson, A., Camacho, N., Zheng, Y., Varghese, A. M., Al-Ahmadie, H., Razavi, P., Chandarlapaty, S., Vallejo, C. E., Vakiani, E., Gilewski, T., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3985 · Cited by 115
Self-citationMolecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
Bayliss, R. W., Choi, J., Fennell, D. A., Fry, A. M., & Richards, M. W. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2117-6 · Cited by 119
The value of research collaborations and consortia in rare cancers
Blay, J., Coindre, J., Ducimetière, F., & Ray-Coquard, I. L. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00388-5 · Cited by 115
Self-citationNovel treatments for anaplastic thyroid carcinoma
Ferrari, S. M., Elia, G., Ragusa, F., Ruffilli, I., Motta, C. L., Paparo, S. R., Patrizio, A., Vita, R., Benvenga, S., Materazzi, G., et al. (2020) · Gland Surgery · doi:10.21037/gs.2019.10.18 · Cited by 117
Baik, C. S., Myall, N. J., & Wakelee, H. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0458 · Cited by 114
Hu, C., & Dignam, J. J. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00086 · Cited by 115
Alam, M., Alam, S., Shamsi, A., Adnan, M., Elasbali, A. M., Al‐Soud, W. A., Alreshidi, M. M., Hawsawi, Y. M., Tippana, A., Pasupuleti, V. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869672 · Cited by 122
Allen, C. E., Laetsch, T. W., Mody, R. J., Irwin, M. S., Lim, M. S., Adamson, P. C., Seibel, N. L., Parsons, D. W., Cho, Y., & Janeway, K. A. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw274 · Cited by 115
Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma
Shanmugam, V., Griffin, G. K., Jacobsen, E. D., Fletcher, C. D. �., Sholl, L. M., & Hornick, J. L. (2019) · Modern Pathology · doi:10.1038/s41379-018-0200-x · Cited by 116
Élez, E., Ros, J., Navarro, J. F., Villacampa, G. J., Moreno-Cárdenas, A. B., Arenillas, C., Bernatowicz, K., Comas, R., Li, S., Kodack, D. P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01976-z · Cited by 111
Self-citationAn efficient basket trial design
Cunanan, K. M., Iasonos, A. E., Shen, R., Begg, C. B., & Gönen, M. (2017) · Statistics in Medicine · doi:10.1002/sim.7227 · Cited by 110
Dong, J., Li, B., Lin, D. C.-C., Zhou, Q., & Huang, D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00230 · Cited by 115
Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121
Self-citationThe landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets
Chong, D. Q., & Zhu, A. X. (2016) · Oncotarget · doi:10.18632/oncotarget.8775 · Cited by 109
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Perez‐Gracia, J. L., Sanmamed, M. F., Bosch, A., Patiño‐García, A., Schalper, K. A., Segura, V., Joaquim Bellmunt, B., Tabernero, J. M., Sweeney, C. J., Choueiri, T. K., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.005 · Cited by 112
Self-citationNew clinical trial designs in the era of precision medicine
Garralda, E., Dienstmann, R., Piris‐Giménez, A., Braña, I., Rodon, J. A., & Tabernero, J. M. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12465 · Cited by 110
Self-citationGouda, M. A., & Subbiah, V. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100788 · Cited by 115
Self-citationRare cancers: a sea of opportunity
Boyd, N., Dancey, J. E., Gilks, C. B., & Huntsman, D. D. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00386-1 · Cited by 107
Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials
Simon, R. M. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.814 · Cited by 107
Hoefflin, R., Geißler, A.-L., Fritsch, R., Claus, R., Wehrle, J., Metzger, P., Reiser, M., Mehmed, L., Fauth, L., Heiland, D. H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00105 · Cited by 114
Targeting BRAF mutations in non-small cell lung cancer
O’Leary, C. G., Andelkovic, V., Ladwa, R., Pavlakis, N., Zhou, C., Hirsch, F. R., Richard, D. J., & O'Byrne, K. J. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.10.22 · Cited by 109
Miyamoto, Y., Suyama, K., & Baba, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040752 · Cited by 110
Moving pan-cancer studies from basic research toward the clinic
Chen, F., Wendl, M. C., Wyczalkowski, M. A., Bailey, M. H., Li, Y., & Ding, L. (2021) · Nature Cancer · doi:10.1038/s43018-021-00250-4 · Cited by 108
Li, Z., Zhao, L., Yu, L., & Wei, M. (2020) · Gastroenterology report · doi:10.1093/gastro/goaa022 · Cited by 110
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
Wheeler, D. A., Takebe, N., Hinoue, T., Hoadley, K. A., Cardenas, M., Hamilton, A. M., Laird, P. W., Wang, L., Johnson, A., Dewal, N., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.015 · Cited by 103
Bayesian basket trial design with exchangeability monitoring
Hobbs, B. P., & Landin, R. (2018) · Statistics in Medicine · doi:10.1002/sim.7893 · Cited by 103
Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
Cardona‐Benavides, I. J., Ramón, C. D., & Gutierrez, N. C. (2021) · Cells · doi:10.3390/cells10020336 · Cited by 107
Yeh, E. A., Greenberg, J., Abla, O., Longoni, G., Diamond, E. L., Hermiston, M. L., Tran, B. H., Galindo, C. R., Allen, C. E., & McClain, K. L. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26784 · Cited by 104
Self-citationTissGDB: tissue-specific gene database in cancer
Kim, P., Park, A., Han, G., Sun, H., Jia, P., & Zhao, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx850 · Cited by 102
Current Insights of BRAF Inhibitors in Cancer
Agianian, B., & Gavathiotis, E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01306 · Cited by 103
Low-grade serous carcinoma of the ovary or peritoneum
Gershenson, D. M. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw085 · Cited by 101
Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review
Al-Jundi, M., Thakur, S., Gubbi, S., & Kłubo-Gwieździńska, J. (2020) · Cancers · doi:10.3390/cancers12082104 · Cited by 105
Roque, A. M., & Odia, Y. (2017) · CNS Oncology · doi:10.2217/cns-2016-0034 · Cited by 100
Histiocytosis and the nervous system: from diagnosis to targeted therapies
Aubart, F. C., Idbaïh, A., Emile, J., Amoura, Z., Abdel-Wahab, O. I., Durham, B. H., Haroche, J., & Diamond, E. L. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab107 · Cited by 100
Self-citationRole of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies
Kim, M. H., & Kim, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2412-x · Cited by 102
Current and future biomarkers in colorectal cancer
Zarkavelis, G. (2017) · Annals of Gastroenterology · doi:10.20524/aog.2017.0191 · Cited by 102
Tolcher, A. W., Peng, W., & Calvo, E. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0349 · Cited by 101
Molecular targeted therapy of BRAF -mutant colorectal cancer
Ducreux, M. P., Chamseddine, A. N., Laurent‐Puig, P., Smolenschi, C., Hollebecque, A., Dartigues, P., Samalin, E., Boige, V., Malka, D., & Gelli, M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919856494 · Cited by 105
Self-citationFrom Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm
Adashek, J. J., Subbiah, V., & Kurzrock, R. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.08.009 · Cited by 99
Self-citationResistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Neel, D. S., & Bivona, T. G. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0007-0 · Cited by 98
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
Chandana, S. R., Babiker, H. M., & Mahadevan, D. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1557145 · Cited by 102
Precision medicine needs randomized clinical trials
Saad, E. D., Paolettí, X., Burzykowski, T., & Buyse, M. E. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.8 · Cited by 98
Lee, L. H., Gasilina, A., Roychoudhury, J., Clark, J. P., McCormack, F. X., Pressey, J. G., Grimley, M. S., Lorsbach, R. B., Ali, S. M., Bailey, M., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.89473 · Cited by 98
Conway, A., Mitchell, C. L., Kilgour, E., Brady, G., Dive, C., & Cook, N. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0332-2 · Cited by 95
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
Ferrara, M. G., Noia, V. D., D’Argento, E., Vita, E., Damiano, P., Cannella, A., Ribelli, M., Pilotto, S., Milella, M., Tortora, G., et al. (2020) · Cancers · doi:10.3390/cancers12051196 · Cited by 101
The Bayesian basket design for genomic variant-driven phase II trials
Simon, R. M., Geyer, S. M., Subramanian, J., & Roychowdhury, S. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.01.002 · Cited by 96
Chiosea, S. I., Thompson, L. D. �., Weinreb, I., Bauman, J. E., Mahaffey, A. L., Miller, C., Ferris, R. L., & Gooding, W. E. (2016) · Cancer · doi:10.1002/cncr.30179 · Cited by 97
RecurrentNRASmutations in pulmonary Langerhans cell histiocytosis
Mourah, S., How‐Kit, A., Meignin, V., Gossot, D., Lorillon, G., Bugnet, E., Mauger, F., Lebbé, C., Chevret, S., Tost, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01677-2015 · Cited by 95
Precision Medicine: A New Paradigm in Therapeutics
Akhoon, N. (2021) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_375_19 · Cited by 116
BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
Garutti, M., Bergnach, M., Polesel, J., Palmero, L., Pizzichetta, M. A., & Puglisi, F. (2022) · Cancers · doi:10.3390/cancers15010141 · Cited by 99
Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0768 · Cited by 94
Self-citationApproaches to modernize the combination drug development paradigm
Day, D., & Siu, L. L. (2016) · Genome Medicine · doi:10.1186/s13073-016-0369-x · Cited by 94
Dalton, W. B., Forde, P. M., Kang, H., Connolly, R. M., Stearns, V., Gocke, C. D., Eshleman, J. R., Axilbund, J. E., Petry, D., Geoghegan, C., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00046 · Cited by 97
Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer
Farago, A. F., & Azzoli, C. G. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.08.02 · Cited by 93
Groisberg, R., Hong, D. S., Holla, V. R., Jankú, F., Piha-Paul, S. A., Ravi, V., Benjamin, R. S., Patel, S., Somaiah, N., Conley, A. P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16845 · Cited by 93
Self-citationPrecision medicine in pediatric oncology: Lessons learned and next steps
Mody, R. J., Prensner, J. R., Everett, J. N., Parsons, D. W., & Chinnaiyan, A. M. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26288 · Cited by 94
Genomically Driven Tumors and Actionability across Histologies:BRAF-Mutant Cancers as a Paradigm
Turski, M. L., Vidwans, S. J., Jankú, F., Garrido‐Laguna, I., Munoz, J., Schwab, R. B., Subbiah, V., Rodon, J. A., & Kurzrock, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0643 · Cited by 90
Self-citationKlempner, S. J., Gershenhorn, B. G., Tran, P. N., Lee, T. K. M., Erlander, M. G., Gowen, K. A., Schrock, A. B., Morosini, D., Ross, J. S., Miller, V. A., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1192 · Cited by 91
Knepper, T. C., Bell, G. C., Hicks, J. K., Padron, E., Teer, J. K., Vo, T. T., Gillis, N., Mason, N. T., McLeod, H. L., & Walko, C. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0195 · Cited by 91
Collignon, O., Gärtner, C., Haidich, A., Hemmings, R. J., Hofner, B., Pétavy, F., Posch, M., Rantell, K. R., Roes, K. C. B., & Schiel, A. E. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1804 · Cited by 91
NCI-60 Cell Line Screening: A Radical Departure in its Time
Chabner, B. A. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv388 · Cited by 90
Raj, N. P., Shah, R. H., Stadler, Z. K., Mukherjee, S., Chou, J. F., Untch, B. R., Li, J., Kelly, V., Osoba, M., Saltz, L. B., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00267 · Cited by 93
Challenging Standard-of-Care Paradigms in the Precision Oncology Era
Subbiah, V., & Kurzrock, R. (2018) · Trends in cancer · doi:10.1016/j.trecan.2017.12.004 · Cited by 90
Self-citationChen, H., Luthra, R., Routbort, M. J., Patel, K. P., Cabanillas, M. E., Broaddus, R. R., & Williams, M. D. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0871 · Cited by 89
EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas
Etemadmoghadam, D., Azar, W. J., Lei, Y., Moujaber, T., Garsed, D. W., Kennedy, C. J., Fereday, S., Mitchell, T. J., Chiew, Y.-E., Hendley, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2224 · Cited by 89
Prevalence and role of HER2 mutations in cancer
Cocco, E., Lopez, S., Santin, A. D., & Scaltriti, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.010 · Cited by 89
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Massironi, S., Pilla, L., Elvevi, A., Longarini, R., Rossi, R. E., Bidoli, P., & Invernizzi, P. (2020) · Cells · doi:10.3390/cells9030688 · Cited by 88
Precision medicine in diabetes: an opportunity for clinical translation
Merino, J., & Florez, J. C. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13588 · Cited by 90
Precision medicine: lessons learned from the SHIVA trial
Tsimberidou, A. M., & Kurzrock, R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00397-6 · Cited by 88
Genomics and the History of Precision Oncology
Doroshow, D. B., & Doroshow, J. H. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.08.003 · Cited by 93
Targeted therapy for lung cancer: Beyond EGFR and ALK
Herrera, M., Serrano‐Gómez, C., Bote, H., & Paz-Ares, L. G. (2023) · Cancer · doi:10.1002/cncr.34757 · Cited by 94
Bardia, A., Gounder, M. M., Rodon, J. A., Jankú, F., Lolkema, M. P., Stephenson, J., Bedard, P. L., Schüler, M., Sessa, C., LoRusso, P. M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0297 · Cited by 89
Hogstad, B., Berres, M., Chakraborty, R., Tang, J., Bigenwald, C., Serasinghe, M. N., Lim, K. P. H., Lin, H., Man, T., Remark, R., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161881 · Cited by 86
Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment
Maître, E., Cornet, É., & Troussard, X. (2019) · American Journal of Hematology · doi:10.1002/ajh.25653 · Cited by 85
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Tan, A. C., Bagley, S. J., Wen, P. Y., Lim, M. K., Platten, M., Colman, H., Ashley, D. M., Wick, W., Chang, S. M., Galanis, E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002459 · Cited by 90
Histology-agnostic drug development — considering issues beyond the tissue
Pestana, R. C., Sen, S., Hobbs, B. P., & Hong, D. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0384-0 · Cited by 82
Recent advances in the management of anaplastic thyroid cancer
Leo, S. D., Trevisan, M., & Fugazzola, L. (2020) · Thyroid Research · doi:10.1186/s13044-020-00091-w · Cited by 87
New Directions in the Therapy of Glioblastoma
Szklener, K., Mazurek, M., Wieteska, M., Wacławska, M., Bilski, M., & Mańdziuk, S. (2022) · Cancers · doi:10.3390/cancers14215377 · Cited by 86
Pathogenesis of cancers derived from thyroid follicular cells
Fagin, J. A., Krishnamoorthy, G. P., & Landa, I. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00598-y · Cited by 88
Sandulache, V. C., Williams, M. D., Lai, S. Y., Lu, C., William, W. N., Busaidy, N. L., Cote, G. J., Singh, R. R., Luthra, R., & Cabanillas, M. E. (2016) · Thyroid · doi:10.1089/thy.2016.0076 · Cited by 84
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Go, R. S., Jacobsen, E. D., Baiocchi, R. A., Buhtoiarov, I. N., Butler, E. B., Campbell, P. K., Coulter, D. W., Diamond, E. L., Flagg, A., Goodman, A. M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0053 · Cited by 84
Self-citationAvigdor, B. E., Beierl, K. F., Gocke, C. D., Zabransky, D. J., Cravero, K., Kyker‐Snowman, K., Button, B., Chu, D. T. W., Croessmann, S., Cochran, R. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0108 · Cited by 81
ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma
Brastianos, P. K., & Santagata, S. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0957 · Cited by 84
Khunger, A., Khunger, M., & Velcheti, V. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618767611 · Cited by 85
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow
Rizzo, A., Ricci, A. D., Tober, N., Nigro, M. C., Mosca, M., Palloni, A., Abbati, F., Frega, G., Lorenzo, S. D., Tavolari, S., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14282 · Cited by 80
Erdheim–Chester disease: a rapidly evolving disease model
Pegoraro, F., Papo, M., Maniscalco, V., Charlotte, F., Haroche, J., & Vaglio, A. (2020) · Leukemia · doi:10.1038/s41375-020-0944-4 · Cited by 84
Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer
Toshimitsu, K., Takano, A., Fujii, M., Togasaki, K., Matano, M., Takahashi, S., Kanai∥, T., & Sato, T. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00984-x · Cited by 84
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 90
Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology
Tao, J. J., Schram, A. M., & Hyman, D. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062016-050343 · Cited by 84
Self-citationRAS and BRAF in metastatic colorectal cancer management
Gong, J., Cho, M. T., & Fakih, M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.12 · Cited by 84
Identification of recurrent mutational events in anorectal melanoma
Yang, H. M., Hsiao, S. J., Schaeffer, D. F., Lai, C. K., Remotti, H. E., Horst, D. A., MANSUKHANI, M. M., & Horst, B. A. J. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.179 · Cited by 80
Implementation and utilization of the molecular tumor board to guide precision medicine
Harada, S., Arend, R. C., Dai, Q., Levesque, J. A., Winokur, T. S., Guo, R., Heslin, M. J., Nabell, L. M., Nabors, B., Limdi, N. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18471 · Cited by 78
Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer
Kollipara, R., Schneider, B. P., Radovich, M., Babu, S., & Kiel, P. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0096 · Cited by 78
Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation
Gounder, M. M., Solit, D. B., & Tap, W. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1511490 · Cited by 78
Metadata
- Authors
- Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., Gervais, R., Elez-Fernandez, M. E., Italiano, A., Hofheinz, R.-D., Hidalgo, M., Chan, E., Schuler, M., Lasserre, S. F., Makrutzki, M., Sirzen, F., Veronese, M. L., Tabernero, J., & Baselga, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut...
- F. Hoffmann-La Roche AG (CH)
- Universitat Autònoma de Barcelona (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-20
- Volume
- 373
- Issue
- 8
- Pages
- 726-736
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4971773
- OpenAlex
- W1846586690
- Semantic Scholar
- abd7e5ae4940f84d6af08e479e67fa7e4788098c
- Cited by
- 1,764
- References
- 31
- Citations by year
- 2026: 55 · 2025: 102 · 2024: 115 · 2023: 122 · 2022: 143 · 2021: 189 · 2020: 210 · 2019: 192 · 2018: 192 · 2017: 241 · 2016: 169 · 2015: 30
- FWCI
- 91.52
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-10-18)
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, basket trials, non-small cell lung cancer, Erdheim-Chester disease, Langerhans cell histiocytosis, colorectal cancer, cetuximab, pleomorphic xanthoastrocytoma, anaplastic thyroid carcinoma, cholangiocarcinoma, ovarian cancer, clear cell sarcoma, targeted therapy
- MeSH terms
- Vemurafenib, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasms, Sulfonamides, Histiocytosis, Disease-Free Survival, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
